Business Context and Reporting Period
This Form 8-K Current Report was filed by PharmAthene, Inc. on May 23, 2014. The filing discloses the entry into a material definitive agreement and the filing of a new registration statement. Note: The request metadata references "Altimmune, Inc.", but the source text explicitly identifies the registrant as PharmAthene, Inc.
Key Financial Metrics and Capital Structure
The filing does not report operational financial metrics such as revenue, profit, cash flow, or margins. The financial data provided relates exclusively to capital raising capabilities:
- ATM Program Increase: The Company increased its Controlled Equity Offering SM Sales Agreement by up to $15.0 million.
- Remaining Availability: Approximately $4.4 million remained available under the initial $15.0 million agreement as of the filing date.
- New Registration: A new Form S-3 Registration Statement was filed covering the potential sale of up to $100.0 million of securities.
Material Changes Versus Prior Period
The primary material change is the expansion of the Company's equity financing capacity:
- Amendment to Sales Agreement: On May 23, 2014, PharmAthene entered into Amendment No. 1 with Cantor Fitzgerald & Co., increasing the aggregate offering price limit of the existing ATM Program by $15.0 million.
- Replacement of Expiring Registration: The Company filed a new Form S-3 to replace the registration statement declared effective on July 27, 2011, which was set to expire on July 26, 2014.
Guidance, Outlook, and Risks
The filing contains no management guidance, earnings outlook, or discussion of operational risks. The document focuses on the mechanics of the securities offering:
- Offering Terms: The Company may offer and sell shares of common stock from time to time through Cantor Fitzgerald & Co. as sales agent.
- Expiration: The prospectus supplement for the initial $15.0 million tranche remains available until the earlier of the sale of all shares or July 26, 2014.
- Legal Disclaimer: The report explicitly states it does not constitute an offer to sell or a solicitation of an offer to buy shares in any state where such offer would be unlawful.
Key Facts for Investor Verification
- Verify the current share price and market capitalization to assess the dilution impact of the potential $100 million new registration and the $15 million ATM increase.
- Confirm the exact amount of the $4.4 million remaining from the initial ATM program that has not yet been sold.
- Review the new Form S-3 Registration Statement (File No. 333-175394) filed on May 23, 2014, for specific terms regarding the $100 million securities offering.
- Monitor the Company's cash burn rate to determine the urgency of utilizing these new financing facilities.